CliffBio
biologic

Vabysmo

faricimab-svoa

Loss of exclusivityJuly 2036projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameVabysmo
Active ingredientfaricimab-svoa
Strength6MG/0.05ML (120MG/ML)
Dosage formInjection
RouteIntravitreal
ModalityBiologic
FDA approvalJuly 2024
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Vabysmo patent cliff — loss of exclusivity July 2036 | CliffBio